Patents expiring in 2041

US 10980885

Method of reducing formation of etanercept aggregates or fragments

Coherus BioSciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982221

Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980846

Use of gram negative species to treat atopic dermatitis

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980847

Compositions and methods for detecting and treating brain injury associated fatigue and altered cognition (BIAFAC)

The Board of Regents of the University of Texas System · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980797

Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

Corcept Therapeutics Incorporated · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980848

Antimicrobial therapy

The Regents of the University of California · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980868

VEGFR-2 targeting immunotherapy approach

Vaximm AG · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981860

Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof

Medshine Discovery Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981894

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980886

Compositions of a polyorthoester and an organic acid excipient

Heron Therapeutics, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980985

Hydrodynamic method and apparatus for delivering fluids to kidney tissues

United States Government as represented by the Department of Veterans Affairs · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980990

Systems, devices, and/or methods for managing transdermal patches

N Brereton Medical Technologies, LLC · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980872

Genetically stable live attenuated respiratory syncytial virus vaccine and its production

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980884

Stable aqueous etanercept composition

Coherus BioSciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981866

Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981896

Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase

The Board of Regents of the University of Texas System · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982001

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981934

Fused heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981902

5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor

Merck MSD (R&D) China Co., LTD. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981986

Fusions of antibodies to CD38 and attenuated interferon alpha

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10983128

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

Providence Health & Services · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982203

Modified factor IX polypeptides and uses thereof

Catalyst Biosciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982212

Conserved HBV and HCV sequences useful for gene silencing

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981970

Chimeric antigen receptor (CAR) comprising a CD22-binding domain

AUTOLUS LIMITED · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981951

Therapeutics for the treatment of glaucoma

Regents of the University of Minnesota · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981915

Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors

Valo Early Discovery, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981906

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

Aclaris Therapeutics, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981855

Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

PTC THERAPEUTICS, INC. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980889

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980861

Glucokinase activator compositions for the treatment of diabetes

VTV THERAPEUTICS LLC · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980841

Methods and compositions for in vivo induction of pancreatic beta cell formation

The Board of Regents of the University of Texas System · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980780

Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

NEUROSENSE THERAPEUTICS LTD. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981977

Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis

THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982230

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

The Regents of the University of California · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982215

Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982232

Diterpene synthases and their use for production of diterpenes

The Regents of the University of California · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980746

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Vertex Pharmaceuticals Incorporated · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982231

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

The Regents of the University of California · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982012

Dissolution of oxidized cellulose

Covidien LP · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10982068

Dendritic macroporous hydrogels prepared by crystal templating

The Board of Regents of the University of Texas System · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980825

Cyclic dinucleotide

Takeda Pharmaceutical Company Limited · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980755

LRH-1 modulators

The Regents of the University of California · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10980895

Ionizable cationic lipid for RNA delivery

ARCTURUS THERAPEUTICS, INC. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981943

Antimicrobial compounds, compositions, and uses thereof

Lakewood Amedex, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10981944

Modulators of 5′-nucleotidase, ecto and the use thereof

Arcus Biosciences, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 3807294

PEPTIDE MIT HEMMENDER WIRKUNG AUF MUSKARINREZEPTOR M3

ACRAF [IT] · Granted Wed Apr 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 3807293

PEPTIDE MIT HEMMENDER WIRKUNG AUF NEURONALE EXOZYTOSE

ACRAF [IT] · Granted Wed Apr 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

AU 2019328599

Compounds and methods for treating fungal infections

BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Thu Apr 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)